Key statistics
As of last trade Biogen Inc (IDP:BER) traded at 152.10, 4.18% above its 52-week low of 146.00, set on Nov 20, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 150.85 |
---|---|
High | 152.10 |
Low | 150.45 |
Bid | 151.20 |
Offer | 152.85 |
Previous close | 151.05 |
Average volume | 874.44 |
---|---|
Shares outstanding | 145.72m |
Free float | 145.50m |
P/E (TTM) | 14.28 |
Market cap | 23.03bn USD |
EPS (TTM) | 11.07 USD |
Data delayed at least 15 minutes, as of Nov 22 2024 14:36 GMT.
More ▼
- Dapirolizumab Pegol Phase 3 Data Presented at the American College of Rheumatology Shows Significant Reduction in Systemic Lupus Erythematosus Disease Activity
- Eisai Receives Positive Opinion from the CHMP in the European Union for Lecanemab in Early Alzheimer’s Disease
- Eisai Presents Data on Benefits of Long-Term Administration of Dual-Acting Lecanemab at the 17th Clinical Trials for Alzheimer’s Disease (CTAD) Conference
- Biogen and Neomorph Announce Multi-Target Research Collaboration to Discover and Develop Molecular Glue Degraders for Alzheimer’s, Rare, and Immunological Diseases
- Biogen Appoints Daniel Quirk, MD, as Chief Medical Officer
- Michael McDonnell, Executive Vice President and Chief Financial Officer to Retire in February 2025
- Biogen Presents Positive Results from Phase 2 IGNAZ Study of Felzartamab in IgA Nephropathy at American Society of Nephrology (ASN) Kidney Week 2024
- Biogen to Present New Data at the Clinical Trials on Alzheimer's Disease (CTAD) 2024 Annual Conference
- Biogen Announces Late Breaker and New Data Presentations at American Society of Nephrology (ASN) Kidney Week 2024
- Biogen Receives U.S. FDA Breakthrough Therapy Designation for Felzartamab for the Treatment of Antibody-Mediated Rejection in Kidney Transplant Recipients
More ▼